ARCHIVES

FDA Should Delay Provenge Decision Pending Definitive Trial Results, ODAC Chairman Writes.

This article is from The Cancer Letter archive.

Vol. 33 No. 16 | April 27, 2007

Download PDF Visit The Full Archive

Related Articles

RFAs: Patient Outcomes “5-A-Day” Program

April 10, 1992

NCCS Networker Volume 1 Issue 1, March 1987

March 12, 1987

Blumenthal Says Action Plan To Issue “New Priority Areas”

October 24, 1996

FDA Advisors Recommend Use of Cytokines GM-CSF, G-CSF In BMT And Chemotherapy

January 4, 1991

Compliance Grants Awarded, Contract Pending On Differences In Black/White Survival

November 19, 1982

In Brief: Senate Committee Confirms Varmus; Albertini Directs Vermont Cancer Center

November 19, 1993